GlaxoSmithKline PLC — Director's Dealing 2026

May 5, 2026

National Storage Mechanism | Additional information

RNS Number : 0889D

GSK PLC

05 May 2026

GSK plc (the 'Company')

2026 Award under the Deferred Investment Award Programme

Notional Award

On 1 May 2026, the Company granted an award over notional Ordinary Shares to Roanne Parry, a Person Discharging Managerial Responsibilities ('PDMR'), under the GlaxoSmithKline Deferred Investment Award programme. The award has been granted upon Ms Parry joining GSK as Chief People Officer and a newly appointed Executive Committee member.

Under the programme, awards are made over notional Ordinary Shares with vesting over a specified period to provide long-term alignment with shareholders. Vesting is subject to the PDMR not having served the Company notice or having been terminated by the Company for cause. Dividends will accrue on the award during the vesting period. On vesting, the award will be paid in cash. The award will vest in two increments: 34.22% of the award will vest on 31 August 2028 and 65.78% of the award will vest on 31 August 2029.

Executive Directors are not eligible to receive awards under the programme.

Transaction notification

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Roanne Parry
b)	Position/status	Chief People Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	A restricted award of notional Ordinary Shares under the Company's Deferred Investment Award programme.
c)	Price(s) and volume(s)		Price(s)	Volume(s)
	£19.01	35,507.628
d)	Aggregated information	N/A (single transaction)
Aggregated volume Price
e)	Date of the transaction	2026-05-01
f)	Place of the transaction	N/A

​ 

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHSSAFFIEMSEFI